Check for updates

Factor structure of the HIV-SM LMIC selfmanagement questionnaire for people living with HIV in low- and middle-income countries

Tegene Legese Dadi^{1,2*}, Girmay Medhin^{3,4} and Mark Spigt^{2,5}

well-being (4 items), self-regulation (6 items), and self-management practices (10 items). **Conclusion** The study re ned the original 32-item HIV-SM LMIC questionnaire to a validated 20-item, threedimensional tool with an acceptable goodness of t. The authors recommend further cross-cultural and predictive validation and adaptation for newly diagnosed HIV patients, those with poor treatment outcomes. **Keywords** HIV-SM LMIC questionnaire, Self-management questionnaire, HIV management, Developing countries

*Correspondence:

Tegene Legese Dadi

tege2004@gmail.com

¹College of Medicine & Health Science, School of Public Health, Hawassa University, Hawassa, Ethiopia

²School CAPHRI, Care and Public Health Research Institute, Maastricht

University, Maastricht, The Netheoverlap, resulting in a 20-item questionnaire. The

Introduction

e introduction of antiretroviral therapy (ART) and substantial investments in care and support of HIV patients have saved lives and transformed the previously life-threatening HIV disease into manageable chronic diseases [1, 2]. According to UNAIDS, HIV treatment has reduced AIDS-related deaths by 69%, equivalent to 20.8 million deaths averted since 2004. In addition, 29.8 million of the 39 million people living with HIV worldwide are receiving life-saving treatment [3]. Despite these positive improvements, the disease remains a major challenge for health systems and patients, with



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articles Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articles Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

2.5 million new HIV infections and 2 million deaths each year [3-5].

People living with HIV face multidimensional problems, including economic, social and psychological problems [6, 7]. HIV-related discrimination has contributed to the loss of employment for more than 50% of people living with HIV in some countries, and up to 21% report being denied health care [7]. ese problems lead to poor quality of life, social alienation and mental health problems [8–11]. A study in Africa showed that HIV patients exposed to stigma were twice as likely to have poor health-related quality of life [8]. In addition to patients, families also face economic strain and poverty, and experience increased caregiving responsibilities as the disease progresses [12-14]. Studies show that HIV reduces household income by 10–14% [13, 15], increases the burden on the health care system [16], increases noncommunicable diseases by up to 10% [17], and increases HIV treatment failure by up to 24% [18, 19]. In developing countries the growing number of HIV patients, coupled with the aging HIV population and the rising risk of multi-comorbidities, is putting additional strain on the healthcare system [2, 20]. ere is also an increase in HIV drug resistance, with 10-25% pretreatment drug resistance to NVP or EFV [21] and 3–29% acquired drug resistance [22].

To address the challenges mentioned, it is essential to rethink the current service delivery model, shifting from provider-centered to patient-centered care. Successful treatment relies heavily on patient engagement for two main reasons: (1) patients have a deeper understanding of their condition [23, 24]; and (2) better outcomes occur when patients are actively involved in managing their care, as they make daily decisions a ecting their health [23, 25]. Empowering patients through self-management encourages responsibility for their health, leading to improved outcomes, higher quality care, reduced burden on the healthcare system, better coping with stigma and discrimination, and fewer hospitalizations [26–30]. For example, in developing countries, the demand for selfmanagement is increasing due to the rising HIV caseload and the chronic nature of the disease [16, 31]. Overall, self-management interventions o er a holistic approach, addressing individual, social, and health system factors and tailoring care to the patient's needs [28, 32-34].

While implementing self-management practices in everyday healthcare, it also becomes essential to assess self-management. For chronic disease patients, it is crucial to use a structured questionnaire to monitor and measure regular self-management practices that can potentially a ect treatment outcomes [35–37]. Several self-management assessment tools exist for evaluating self-management practices among HIV patients. Yet, many of these tools have limitations and lack

comprehensiveness. Some are tailored to speci c populations, such as a tool developed by Talitha et al. [38], which focuses on adolescents, and one by Wabel et al., which targets women in developed countries [39]. Other tools focus on speci c health-related issues, such as the tool by Kenneth et al., which assesses perceived medical conditions [40], or the tool by Mallory et al., which emphasizes adherence [41]. However, there is a lack of reliable, comprehensive, and valid questionnaires that accurately assess self-management in the context of developing countries [28, 42–44].

e aim of this research is to extend the groundwork laid by previous research on the development of HIV-SM LMIC questionnaire, which involved item generation and testing of its face and content validity for the context of developing countries [45]. e primary objective of this study is to pilot and assess the construct validity of the HIV-SM LMIC questionnaire.

Methods

Study design

e validation process of the HIV-SM LMIC questionnaire employed an observational research method, speci cally a cross-sectional study design, to collect data from selected HIV patients who visited health facilities for healthcare services in Ethiopia. Study participants were selected from Hawassa University Comprehensive Specialized Hospital (HUCSH), Adare General Hospital, and Millennium Health Center in two rounds study (for exploratory factor analysis and con rmatory factor analysis).

Study setting

Ethiopia is the second most populous country of Africa and ranks 12th in the world with a population of more than 105 million [46]. e country experiences rapid population growth (2.6%) has a young age structure, and a high dependency ratio, with signi cant rural-urban differences [47]. Ethiopia's healthcare system is organized into three tiers: primary, secondary, and tertiary levels of care. Primary health care units provide essential services, general hospitals o er secondary care, and specialized hospitals deliver tertiary care [48]. e study was conducted at HUCSH, a tertiary-level facility; Adare General Hospital, a secondary-level facility; and Millennium Health Center, a primary-level facility. ese facilities are selected because of various reasons including diversity of HIV patients from where comes from various regions; and levels of the health facility which will give us the opportunity to acquire di erent contexts.

HUCSH serves approximately 5 million people from the southern regions of Ethiopia, predominantly drawing users from Sidama, Oromia, Southwest Ethiopia, and Somali regions. e hospital, equipped with over 500 beds, has registered 7,967 HIV patients since the initiation of ART, with 2,760 active adult HIV patients (1,726 female and 1,072 male) during the current study. Adare General Hospital serves a catchment population of approximately 1.3 million, primarily from the Sidama region and partly from the West Arsi zone (Oromia region). With 120 beds, the hospital has registered 3,205 HIV patients since the inception of ART, among whom 2,434 (1,559 females and 875 males) are active adult HIV patients during the current study. Millennium Health Center provides health services to around 83,215 individuals from two sub-cities and ve kebeles of Hawassa city. Since its establishment, the health center has registered 892 ART patients, with 601 active adult HIV patients (401 female and 200 male) during the current study.

Context of the study

is study is part of a series of studies aimed at developing a comprehensive self-management questionnaire tailored for HIV patients in developing countries. As part of this undertaking, three research outputs have already been produced which was the basis for the current study; two published papers [23, 24], and the development and validation (face and content validation) of HIV-SM LMIC questionnaire, currently under review [45]. e present study delves into evaluating the construct validity of the 32-item HIV-SM LMIC questionnaire through two stages: a rst-round study to explore its factor structure using exploratory factor analysis, followed by con rmatory factor analysis.

Sample size and recruitment of study participants

Both the rst-round study and con rmatory factor analysis were conducted among adult HIV patients, speci cally those above 18 years of age, who were in follow-up appointments at the health facilities. Newly diagnosed HIV patients were not included in both rounds of the assessment. e sample size for both rst-round study and con rmatory factor analysis was determined based on recommendations provided by various authors. Different authors suggest minimum sample sizes ranging from 100 to 1,000 for testing questionnaire reliability and validity in exploratory and con rmatory factor analysis [49, 50]. However, most agree that a sample size between 200 and 300 is su cient [50]. Following these recommendations, the rst-round study for exploratory factor analysis included a sample size of 260 patients, and 300 patients for the con rmatory factor analysis. Patients were enrolled in the study during their visits to the health facility, after completing their service delivery. Before starting the interview, patients were informed about the study and consented to participate. Enrolment was conducted consecutively until the sample size was reached.

The process of data collection

ere were two rounds of data collection and one round of discussion with the data collectors. e rst round of data collection was to collect data that could be used for exploratory factor analysis (EFA), and the second round was to collect data that could be used for con rmatory factor analysis (CFA). Before commencing data collection, the data collectors were trained on the questionnaires and began data collection once they were thoroughly familiar with them. e discussion with data collectors was conducted after the rst round of data collection. Notes from the discussion were recorded item by item in a notebook.

Both rounds of quantitative data were collected through face-to-face interviews by trained data collectors, who were healthcare providers within the ART clinics of the study health facilities. Data collection tools were prepared using the Kobo Collect electronic data entry template. Data were collected using smart mobile phones, and the data collectors sent the data to the server daily. A discussion with the data collectors was held after the completion of the pilot data or rst-round of data collection. e main focus of the discussion was on the items and patients' responses and with the aim of identifying areas for improvement for the second round of data collection.

Quality assurance of the data

e data quality assurance (DQA) was ensured through various measures including a comprehensive training for data collectors to ensure their understanding of the items, along with pre-testing of the survey tools. Field supervisor provided supervision to all data collectors to check completeness and quality. e researcher (TLD) closely monitored the data collection process daily to ensure data quality using data quality queries. Any records identi ed with data quality issues during data collection were discussed with data collectors for corrections. Daily feedfactor analysis rotation methods. e number of factors selected was based on the dimensions of the Individual and Family Self-Management eory (IFSMT) model. Based on the results of the EFA, a discussion was held with the data collectors to gather their reections on their interview experiences and patients' responses to each item. Discussion points included how well the items captured the correct responses from patients, issues identied with items or their response categories or scales, the

 Table 1
 Socio-demographic characteristics of HIV patients that participated in the study

Variable	Categories	First-round study # (%)	Second round study # (%)
Name of the	HU CMHS hospital	174 (66.67)	136 (45.33)
health facility	Adare Hospital	85 (32.57)	99 (33.00)
	Millenium Health center	2 (0.77)	65 (21.67)
Age of	18–29 years	38 (15.14)	38 (12.92)
respondent	30–39 years	92 (36.65)	120 (40.82)
	40–49 years	90 (35.85)	100 (34.02)
	50 + years	31 (12.35)	36 (12.24)
Sex of the	Female	180 (71.71)	204 (68.00)
patient	Male	71 (28.29)	96 (32.00)
Marital status	Single	27 (10.34)	21 (7.00)
	Currently Married	139 (53.26)	170 (56.67)
	Widowed	38 (14.56)	54 (18.00)
	Divorce	57 (21.84)	55 (18.33)
Level of	No formal education	22 (8.76)	30 (10.20)
education of the patient	Primary education (1–8 grades)	77 (30.68)	96 (32.65)
	Secondary education (9–12 grades)	93 (37.05)	95 (32.32)
	Level I-V	36 (14.34)	45 (15.30)
	Degree and above	23 (9.16)	28 (9.52)
Occupation	Housewife	55 (21.91)	52 (17.69)
	Merchant/Self-employed	78 (31.08)	105 (35.71)
	Student	12 (4.78)	5 (1.70)
	Government/private employee	62 (24.70)	75 (25.51)
	Daily laborer	33 (13.15)	46 (15.65)
	Others	11 (4.38)	11 (3.74)
Extreme	Below extreme poverty line	158 (60.54)	148 (49.33)
Poverty line	Above extreme poverty line	103 (39.46)	152 (50.67)
Travel	Less than 10 KMs	156 (59.77)	208 (69.33)
distance in KM to come	11–25 KMs	37 (14.18)	34 (11.33)
	26–50 KMs	27 (10.34)	23 (7.67)
to the health	51–100 KMs	13 (4.98)	14 (4.67)
facility	101 + KMs	28 (10.73)	21 (7.00)
% of monthly	<=1% of income	89 (36.93)	144 (49.32)
income	1.1-5% of income	103 (42.74)	119 (40.75)
utilized for	5–10% of income	18 (7.47)	16 (5.48)
transport	> 10% of income	31 (12.86)	13 (4.45)

HU CMHS: Hawassa University College of Medicine and Health Science; KM: Kilometer importance of the items, and types of responses. Using the data collected in the second round, con rmatory factor analysis (CFA) was conducted using maximum likelihood estimation.

Results

A total of 561 HIV patients (261 in the rst round and 300 in second round study) were interviewed for the validation and investigation of factor structure of HIV-SM LMIC questionnaire.

Characteristics of study participants

Socio-demographic characteristics

In both rounds of data collection, most patients were in the age range of 35–39 years, with the fewest patients coming from the 18–24 years age range. More than twothirds of the respondents were female in both rounds, and one-third had a minimum of secondary school level of education. Around one-third were merchants or selfemployed, nearly half of patients are below the extreme poverty line. More than 40% of respondents in the rst round and 30% in the second round had to travel for more than 10 km to visit the health facility. Approximately 11% in the rst round and 7% of HIV patients in the second round had to travel more than 100 km to reach the health facility. More than 20% in the rst round and over 10% in the second round spend more than 5% of their monthly income on travel to the health facility (Table 1).

Clinical characteristics of study participants

Table 2 describes the clinical characteristics of the study participants enrolled in two rounds. More than one in seven of HIV patients included in both two rounds of study did not disclose their HIV status to their family or peers. e majority in the rst round (28.3%) were on ART regimens for 10-15 years, whereas most of the respondents included in the second round were on ART for 5–10 years. Over three-fourths of HIV patients in both rounds had changed their ART regimen at least once. Around 7% of HIV patients were on second-line ART regimens. Most patients in both rounds of data collection had undetectable viral loads, which is below 50 copies of the virus per ml. More than 12% of HIV patients had at least one non-communicable disease. Additionally, more than one- fth of HIV patients experienced at least a mild form of psychological distress.

Validation of items of HIV-SM LMIC questionnaire

Figure 1 illustrates the ow of the validation process. During the rst-round study with exploratory factor analysis, 4 items were dropped, and one item was revised. In the CFA, 4 items were reclassi ed based on the EFA results, and 8 items were dropped, resulting in a nal

 Table 2
 Clinical characteristics of HIV patients that participated in the study

Variable	Categories	First round study # (%)	Second round study # (%)
Disclosed HIV	No	40 (15.33)	41 (13.67)
status	Yes	221 (84.67)	259 (86.33)
Months on	Less than 1 year	17 (6.77)	7 (2.38)
ART	Between 1–5 years	53 (21.12)	66 (22.44)
	Between 5–10 years	64 (25.5)	92 (31.29)
	Between 10–15 years	71 (28.29)	84 (28.57)
	More than 15 years	46 (18.33)	45 (15.31)
Baseline viral	Below 50 copies	236 (94.02)	268 (91.16)
load	51–499 copies	6 (2.39)	9 (3.06)
	500 + copies	9 (3.59)	17 (5.78)
Frequency	No change	62 (24.7)	78 (26.53)
of regimen	One times	144 (57.37)	155 (52.72)
change	Two times	25 (9.96)	50 (17.01)
	3 + times	20 (7.97)	11 (3.74)
Current ART	First line ART regimen	233 (92.83)	272 (93.16)
regimen type	Second line ART regimen	18(7.18)	20(6.80)
Last two	Below 50 copies	236 (94.02)	273 (92.86)
viral load:	51–499 copies	7 (2.79)	9 (3.06)
preceding	500 + copies	8 (3.19)	12 (4.08)
Last two viral	Below 50 copies	246 (98.01)	287 (97.62)
load: recent	51–499 copies	3 (1.20)	7 (2.38)
	500 + copies	2 (0.80)	
Presence of	No	220 (87.65)	255 (86.73)
NCD	Yes	31 (12.35)	39 (13.27)
Psychological	None	204 (78.16)	221 (73.67)
distress	Mild	52 (19.92)	67 (22.33)
	Moderate	1 (0.38)	9 (3.00)
	Severe	4 (1.53)	3 (1.00)

ART: Antiretroviral Therapy; NCD: Noncommunicable disease

20-item HIV-SM LMIC questionnaire. e following two subsections describe the results from EFA and CFA.

Exploratory factor analysis

As Table 3 showed that there is no signi cant di erence in terms of the 32 items included in the rst and second round patients. e initial construct validity of the 32-item HIV-SM LMIC questionnaire (6 items in contextual, 15 in process, and 11 in the proximal outcome dimension) was assessed using exploratory factor analysis (EFA) on rst round study collected from 261 HIV patients. e number of factors to be extracted from the data was set to three, corresponding to these dimensions.

e EFA was conducted using the iterated principal factors method, with quartimin oblique rotation to generate the results. We have chosen quartimin oblique rotation because the factors are correlated in which one of the factors a ects the other factor. e factors that will be identi ed through EFA are not independent that is why we have used quartimin oblique rotation. e sample adequacy test showed a good overall value of 0.82. e rotated factor loading of items within the three dimensions are presented in Fig. 2.

In the EFA, the dimensions of some items from their original categorization were changed and 6 items did not load onto any one of the three factors (Table 3). Four of these 6 unloaded items were dropped from the subsequent validation process. However, the two unloaded items (PSMB2 and PSMB12) were retained because they were considered important based on their content.

Findings from qualitative discussion conducted after EFA

Discussions were held with the data collectors regarding each item before commencing the second round of data collection which was used for con rmatory factor analysis (CFA). Out of the six items that either did not load or had loadings below 0.3, four were omitted due to their limited importance to the questionnaire or redundancy, as they were covered by other items, resulting in a 28-item HIV-SM LMIC questionnaire. e remaining two items were retained for CFA due to their perceived signi cance. Additionally, one item (PSMB1) was revised to maintain its original concept, as data collectors had interpreted it di erently. Further details and explanations can be found in Supplementary File A.

Another signi cant issue discussed with the data collectors was the inconsistency in patient responses across di erent items. Patients occasionally provided con icting answers, often due to fear of judgment from providers or other personal reasons. For instance, they might initially assert strong adherence to medication but later disclose instances of missed doses. To mitigate this, we stressed the importance of data collectors capturing the genuine characteristics and realities of the patients.

Self-management status of HIV patients

e responses to the 32-item HIV-SM LMIC questionnaire from study participants in the rst and second rounds of the study are summarised in Table 3. All the 32 items have ve response scales, and the rst two categories (response 1 and 2) are categorised as low, while responses from 3 to 5 are categorised as high. In the rst round of the study the responses of the study participants are high for each scale ranging from 78.9 to 99.6%. In the second round of the study the responses of the study participants are high for each item ranging from 75.7 to 99.7%. In the rst round of the study, more than 90% of respondents responded high for 23 (72%) of the 32 items, and in the second round, more than 90% of respondents responded high for 24 (75%) items.




Fig. 1 HIV-SM LMIC questionnaire validation process

Con rmatory factor analysis

Con rmatory factor analysis (CFA) was conducted using 28 items from the HIV-SM LMIC questionnaire. Five different types of CFA models (1 initial, 3 improved, and 1 nal CFA model) were sequentially tted to generate the nal list of items for the HIV-SM LMIC questionnaire. Supplementary File B presents the initial tted and improved CFA models. Table 4 outlines the nal CFA model used to create the de nitive HIV-SM LMIC questionnaire.

e initial CFA model was constructed based on the results of the EFA, incorporating the three dimensions of the questionnaire. However, the model goodness of t was not signi cant. Consequently, post-estimation statistics (i.e. Modi cation Indices (MI)), were employed to explore potential enhancements to the model. One notable observation was the potential misclassi cation of items across the three dimensions. Subsequently, four items displayed notably high MI values with their original EFA dimensions. ese four items were then reclassi ed into new dimensions, after checking their alignment with the theoretical rationale of the respective dimensions. Table 5 describes reclassi cation of these items. As depicted in Table 4, the nal CFA model resulted in the removal of 8 items to produce a 20-item HIV-SM LMIC questionnaire (4 items in awareness and wellbeing, 6 in self-regulation, and 10 in self-management practices dimensions). Despite having coe cients or loadings of less than 0.40, ve items were retained in the nal version of the questionnaire because of their theoretical importance. ese items include CIF2 in awareness and wellbeing, PSR14 in self-regulation, and PSMB7, PSMB8, and PSMB15 in self-management practices dimension. Furthermore, seven items exhibited loading coe cients of 0.70 or higher, four items had coe cients between 0.60 and 0.69, the loading of three items fell within the range of 0.50 and 0.59, and one item had a loading of 0.42.

HIV-SM LMIC nal item characteristics with key patient attributes

e 20 nal items of HIV-SM LMIC questionnaire categorized into high and low in which the response and ve categorized together as high the rest response categories as low. Some key patient characteristics which can measure treatment outcome of HIV patients were observed by means of the 20 items as shown in Fig. 3. ere is no

Table 3 Exploratory factor analysis result - item loadings and grouping

ltem code	Questions	% of PL with hi	gh**	Loadings	IFSMT dimen-
		item sc	ore.		sion
		1st round	2nd round		
EFA new	dimension 1	Touriu	Tound		
CIF3	Do you feel you have enough time to look after your health (e.g. taking medicines, rest…) despite your family responsibilities?	97.7	96.7	0.39	Context
CIF6	Do you agree that staying physically active (any movement at any time such as walking, cycling, and others for at least 2 days per week) is an important part of HIV care?	98.5	98.7	0.44	
РКВЗ	Do you believe that you have a clear understanding of HIV?	98.1	98.0	0.67	Process
PKB4	How often do you forget to take your medicine?	97.3	98.3	0.64	
PKB6	Do you agree that su cient sleep is important for HIV care?	96.6	98.7	0.41	
PRN11	Do you trust the advice the health care providers give about your health and HIV?	99.6	99.0	0.39	
PSF3	Do you agree that you have a trustworthy person to turn to if you have problems?	91.2	90.0	0.35	
PSR1	Have you been encouraged to disclose your HIV status to your close family or peers?	88.9	89.7	0.32	
PSR14	Do you agree that you Integrate your treatment plan into your daily routine?	99.6	99.7	0.43	
PSMB1	To what extent do you use the knowledge of your current conditions to better manage HIV?	98.1	96.7	0.52	Proxima Outcome
	dimension 2				
CS3*	Do you frequently feel alienated or isolated from others because of your HIV?	86.6	75.7	0.52	Context
CS5*	Do you frequently worry about disclosing your HIV to close family or peers?	78.9	80.7	0.46	
CIF2	Do you agree that reducing use of substances (drinking alcohol / using drugs / smoking khat or cigarettes) is critical for better HIV management?	97.3	99.0	-0.35	
SR2*	How often do you skip or miss your medication when you are with people?	90.8	96.0	0.71	Process
PSR4*	How often do you forget to take your medicine?	89.7	89.3	0.71	
PSR5*	How often do you decide not to take your medicine?	91.6	88.7	0.72	
PSR23*	How often do you experience the feeling of hopelessness, depression, sadness or anxiety or related symptoms due to your illness?	89.3	94.7	0.70	
PSMB2	How strong are you when society excludes or isolates you from your social life due to your illness?	91.6	91.3	Not loaded	Proxima outcom
EFA new	dimension 3				
PSR12	Do you agree that you should stick to your treatment plan even when side e ects, which are not life threatening, bother you?	97.7	99.3	0.35	Process
PSMB7	To what extent are you self-disciplined enough to perform regular exercise?	78.2	85.7	0.39	Proxima
PSMB8	To what extent have you modi ed your diet (eating vegetables, fruits, or balanced diet what is available at home) to better manage HIV?	86.2	86.0	0.44	Outcom
PSMB12	To what extent are you able to stop unpleasant thoughts and frustration (e.g. anger, fear, sad- ness) due to your illness?	82.8	87.7	Not loaded	
PSMB15	, , , , , , , , , , , , , , , , , , , ,	91.2	93.0	0.47	
PSMB19	To what extent do you strive to nd e ective solutions to problems related to your HIV disease management?	96.9	95.3	0.45	
PSMB21	To what extent are you implementing the HIV treatment strategy told to you by your health care providers?	96.6	98.3	0.49	
PSMB22	To what extent are you adhering to treatment medications uptake?	93.1	94.7	0.62	
PSMB23	To what extent are you adhering to medical follow-up schedules or appointments?	95.4	96.0	0.78	
PSMB24	To what extent do you take responsibility for your own health care?	97.3	97.0	0.60	
	l items from further validation				
CP1	Do you agree that the health facility o ers the services you require most of the time, such as lab tests for viral load or CD4?	97.3	99.3	Not loaded	Context
PR8	Do you agree that the health care provider pays enough attention to your social or emotional problems (e.g. asking reasons for sadness or feelings)?	91.6	91.7		Process
PSF1	Do you agree that it is important for you to attend support groups for your HIV management strategy?	87.7	96.0		
PSR18	How important is spirituality as a motivator to manage HIV?	100.0	99.7		

*Reverse scored items; EFA: exploratory factor analysis; IFSMT: Individual family self-management theory; ** If patients scored 4 or 5 on the Likert scale, they were considered high, and if they scored 1–3, they were considered low




Fig. 2 Rotated factor loading of items

di erence between mean of 20items among patient who disclosed and undisclosed their HIV status. e same is true also for occurrence of treatment failure and presence of NCD. However, there is signi cant di erence of means of the items by psychological distress, occurrence of opportunistic infection and poor adherence history. Patients with psychological distress, opportunistic infection and history of poor adherence have low mean values than their counterparts.

Four items including CS3, PSR4, PSR5, and PSR23 have reverse score. Items include PSMB7, CS3_new, and PSMB8 have the lowest values as compared to other items, whereas PKB6, PSR12, and PSR14have the highest values. Table 6 shows the crosstabulation of the 20 nal items with the key treatment outcome variables. More details of crosstabulation between patient characteristics and 20 items is described in supplementary le D.

Discussion

e 32-item HIV-SM LMIC questionnaire underwent further validation for content and construct validity through two rounds of data collection involving 561 HIV patients. During this process, 12 items were dropped (4 during the exploratory factor analysis [EFA] and 8 during the con rmatory factor analysis [CFA]), four items were reclassi ed from the EFA suggested dimension classi cation to other dimensions based on the CFA results, and one item was revised. is resulted in a 20-item HIV-SM LMIC questionnaire with three dimensions: awareness and wellbeing, which has 4 items; self-regulation (i.e. Emotional management and compliance with the treatment plan), which has 6 items; and self-management practices, which has 10 items. e nal CFA model demonstrated an acceptable level of goodness of t.

e ultimate three dimensions in our HIV-SM LMIC questionnaire and the IFSMT model, which formed the basis for our studies, di er in several aspects [45]. e rst discrepancy is in the number of dimensions: the IFSMT model has four dimensions (context, process, proximal outcome and distal outcome), whereas the HIV-SM LMIC questionnaire has three dimensions. e second discrepancy relates to the shift and merging of some dimensions in the new questionnaire that di er from the original IFSMT model. For example, the awareness and




Fig. 3 Mean of items across patient attributes

well-being dimension consists of items originally developed in the context and process dimensions. e reasons for this discrepancy may be that the IFSMT model has not been tested, does not re ect current practice, which is in contrary with the new HIV-SM LMIC dimensions, and was developed based on developed country contexts.

ese ndings highlight the need to revise the IFSMT to better re ect the realities faced by HIV patients, families, and service providers in developing countries. e current study can contribute signi cantly to this regard, especially for the contexts of developing countries.

e decision to drop or retain items was based both on the results of statistical analysis (EFA and CFA) and theoretical rationales, as usually recommended [51-53]. Some items with low factor loading were kept in the nal 20-item HIV-SM LMIC questionnaire due to their theoretical importance. Among the 12 items that were dropped, some items had high factor loading but were excluded due to overlapping concepts, or lack of signi cance to the context. Relying solely on statistical results or theoretical assumptions can result in an inaccurate and unreliable questionnaire. Psychometric tools measure personality traits indirectly through responses to a range of items [43], which can introduce various errors, including measurement errors and lack of sensitivity to population variations, a ecting the accuracy and reliability of the items [52]. In producing the nal 20-item questionnaire, greater emphasis was placed on theoretical rationales for keeping the items rather than making decisions purely based on statistical results.

e inclusion of various key areas of self-management practices is essential, as revealed by the opinions of experts, service providers, and patients themselves [23, 24]. is helps to address the multifaceted needs related to the chronic condition and improve their quality of life [16, 37]. us, self-management questionnaires should be comprehensive, assessing all key areas and capturing context-speci c conditions [23, 36]. e current 20-item HIV-SM LMIC questionnaire with three dimensions is comprehensive and covers key areas of self-management.

e "awareness and wellbeing" dimension includes items related to dedicating time for treatment, the importance of sleep and physical activity, and a clear understanding of disease-related issues. e "self-regulation" dimension comprises items related to resilience to stigma, mental distress, emotional problems, daily routines, and treatment adherence. e third dimension includes items related to self-management activities. ese dimensions encompass items that should be used to assess selfmanagement as mentioned by various authors [39–41, 54-56].

When compared to other self-management questionnaires developed elsewhere [39, 40, 57], the HIV-SM LMIC questionnaire is within the context of developing countries to assess various dimensions of self-management. Questionnaires developed in the context of developed countries often do not re ect the contexts of developing countries, whereas the HIV-SM LMIC questionnaire is based on a comprehensive theoretical framework and tested in the contexts of developing countries. However, before implementing the questionnaire in other low- and middle-income countries, it remains important to conduct cross-cultural validation. Di erent cultures, social norms, and practices in uence how questions are understood and how responses vary [58]. erefore. it is crucial to test the items across various cultures to

Page	11	of	14

nal iten
the 20
n with 1
abulatio
s crossta
outcomes
Key treatment outcomes crosstabulation w
Key
Table 6

Table 6 Key	Table 6 Key treatment outcomes crosstabulation with the	nes crosstabi	ulation wi	th the 20	20 nal items										
Factor	Final items	Key chara	cteristics (Key characteristics of the patient	nt										
		Disclosed HIV status	VIH	Psychological distress	ogical distr	ess		Treatment resistance	reatment failure or Opportunistic esistance infections	Opportu infectio	unistic 1S	Poor adherence	herence	Presence of NCD	e of
		No	Yes	None	Mild	Moderate Severe	Severe	No	Yes	No	Yes	No	Yes	No	Yes
Awareness and CIF3	d CIF3	84.0	82.9	85.4	78.2	60.0	57.1	81.5	93.3	83.4	78.6	83.5	81.0	82.7	85.7
wellbeing	CIF6	91.4	83.5	86.4	80.7	70.0	71.4	85.0	82.7	84.8	83.3	86.6	76.0	83.9	0.06
	PKB3	72.8	76.7	79.1	69.7	50.0	42.9	74.1	89.3						

increase the relevance, comparability, and reliability of the HIV-SM LMIC questionnaire [59, 60].

e 20-item HIV-SM LMIC questionnaire, speci cally designed for chronic HIV patients, is unique in its ability to assess the complex nature of self-management among HIV patients in low- and middle-income countries. Some items that characterize speci c groups of HIV patients, such as newly diagnosed patients who behave di erently than chronic HIV patients, were dropped during the analerefore, the HIV-SM LMIC questionnaire should vsis. be customized di erently for newly diagnosed HIV patients. In addition, almost three-quarters of the items were rated highly by more than 90% of respondents, indicating homogeneity of patients in key characteristics. For instance, 98% of HIV patients have an undetectable viral load, and 93% are on a rst-line ART regimen. is is mainly because respondents were recruited from outpatient ART clinics, where patients come to re ll their ART drugs—these patients are not sick or experiencing poor treatment outcomes. Future validation of the HIV-SM LMIC questionnaire should therefore include patients with current opportunistic infections, those on second or higher ART regimens, or those admitted to the hospital.

is study does not present the scoring method or cuto points for the HIV-SM LMIC questionnaire, as multiple validation studies are needed to demonstrate the association between the self-management item scores and key HIV treatment outcomes, such as quality of life, adherence, and the occurrence of opportunistic infections. Determining cut-o points is part of predictive validity, which should be established after validating the questionnaire in di erent settings, and contexts [61–63]. Validation of the HIV-SM LMIC questionnaire with measures of HIV treatment outcomes, such as quality of life, adherence, and incidence of opportunistic infections in di erent settings, is critical.

Strength and limitation of the study

It is known that development and validation of new questionnaires should adhere to an iterative process guided by robust scienti c methodologies. In this study, the authors adopted a phased approach and rigorous scienti c methods to develop and validate the HIV-SM LMIC questionnaire. Moreover, the sample recruited for the validation process in two rounds was optimal, encompassing a diverse group of patients from various levels of health facilities, including health centers (primary level), general hospitals (secondary level), and specialized referral hospitals (tertiary level). However, the study is not without limitations. Social desirability bias and a sense of urgency during interviews with HIV patients might have in uenced the responses to items rated high. To mitigate these limitations, data collectors provided detailed explanations about the aims of the study to the participants. e authors also closely monitored the data collection process daily to ensure data quality, utilizing data quality queries. Whenever issues arose, the authors communicated with the data collectors daily to promptly resolve them.

Conclusion and recommendation

e 32-item HIV-SM LMIC questionnaire underwent both an exploratory factor analysis (EFA) phase and a con rmatory factor analysis (CFA) phase, resulting in a e decire ned 20-item HIV-SM LMIC questionnaire. sion to drop 12 items during the validation process was based on their factor loadings and concrete rationales. Some items shifted from their original dimensions to other dimensions, underscoring the need for a revision of the IFSMT model to better align with the actual realities faced by patients, families, and providers. Consequently, the authors recommend further testing and validation of the IFSMT model. Moreover, the HIV-SM LMIC questionnaire should be validated in other low- and middleincome countries to ensure cross-cultural and predictive validity. Since the current iteration of the questionnaire assesses the self-management practices of chronic HIV patients, it should be adapted for newly diagnosed HIV patients as well. Moreover, it should be validated among HIV patients with poor treatment outcomes, who are admitted or have virological failure or have opportunistic infections.

Supplementary Information

The online version contains supplementary material available at https://doi.or g/10.1186/s12981-024-00676-7.

Supplementary Material 1	
Supplementary Material 2	
Supplementary Material 3	
Supplementary Material 4	

Acknowledgements

The authors would like to thank all data collectors and patients participated in two rounds of data collection process. I thank also Hawassa University and Maastricht University.

Author contributions

All authors contributed to the study during the conception, design, data analysis and drafting of the manuscript. TLD was involved in the whole process of the study. GM and MS were involved in critically reviewing the manuscript. All authors read and approved the nal manuscript.

Funding

This study did not receive funding.

Data availability

Data will be provided by the corresponding author (tege2004@gmail.com) upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was abided by all national ethical standards in its entirety and approved by the Institutional Review Board (IRB) from College of Medicine and Health Sciences, Hawassa University in Ethiopia (Ref. No. IRB/337/15). Permission in the health facilities was granted before contacting the health service providers. All the experts were informed about the bene ts and risks of the study and informed consent was obtained. Participation in this study was based on willingness of experts to be involved. Die erent methods such as deidenti cation or excluding names or other identi ers from the main data was used to ensure privacy and con dentiality.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 12 July 2024 / Accepted: 18 November 2024 Published online: 21 December 2024

References

- 1. Tabitha W, Mahungu AJRaMAJ. HIV as a chronic disease. Clin Med. 2009;9(2).
- Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–33.
- UNAIDS. The path that ends AIDS: UNAIDS Global AIDS Update 2023. Geneva: Joint United Nations Programme on HIV/AIDS; 2023.
- WHO. Number of death due to HIV/AIDS 2021 [https://www.who.int/data/gh o/data/indicators/indicator-details/GHO/number-of-deaths-due-to-hiv-aids
 UNAIDS. Global HIV statistics: Fact sheet 2023. 2023.
- McIntosh RC, Rosselli M. Stress and coping in women living with HIV: a meta-
- analytic review. AIDS Behav. 2012;16(8):2144–59.
- 7. UNAIDS. HIV stigma and discrimination. 2021.
- Parcesepe AM, Nash D, Tymejczyk O, Reidy W, Kulkarni SG, Elul B, Gender. HIV-related stigma, and health-related quality of life among adults enrolling in HIV care in Tanzania. AIDS Behav. 2020;24(1):142–50.
- Holzemer WL, Human S, Arudo J, Rosa ME, Hamilton MJ, Corless I, et al. Exploring HIV stigma and quality of life for persons living with HIV infection. J Association Nurses AIDS Care: JANAC. 2009;20(3):161–8.
- Logie C, Gadalla TM. Meta-analysis of health and demographic correlates of stigma towards people living with HIV. AIDS Care. 2009;21(6):742–53.
- Oskouie F, Kashe F, Ra i F, Gouya MM. Qualitative study of HIV related stigma and discrimination: what women say in Iran. Electron Physician. 2017;9(7):4718–24.
- Economic Commission for Africa. The impacts of HIV/AIDS on families and communities in Africa. In: Commission on HIV/AIDS and Governance in Africa, editor. 2021.
- M. FSaK-MF. The impact of HIV/AIDS on labor markets, productivity and welfare in Southern Africa: a critical review and analysis. Afr J Agric Res. 2011;6(10).
- 14. ILO. HIV/AIDS and poverty: the critical connection. 2005.
- 15. Haacker GSaM. HIV/AIDS: the impact on poverty and inequality. International Monetary Fund; 2006.
- van Jose en GMK, Bermejo R, Kegels G, Katharina Hermann and Wim Van Damme. The growing caseload of chronic life-long conditions calls for a move towards full selfmanagement in low-income countries. Globalization Health. 2011;7(38).
- Drago F, Soshnik-Schierling L, Cabling ML, Pattarabanjird T, Desderius B, Nyanza E et al. Characterizing blood pressure trajectories in people living with HIV following antiretroviral therapy: a systematic review. HIV Med. 2023;2023:1–9.
- Mar Pujades-Rodri 'guez SB, Line Arnould MAW, Brinkhof, Alexandra Calmy. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304(3).
- Agegnehu CD, Techane MA, Mersha AT, Atalell KA. Burden and associated factors of virological failure among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis. AIDS Behav. 2022;26(10):3327–36.
- 20. Hacker K. The burden of chronic disease. Mayo Clin Proc Innov Qual Outcomes. 2024;8(1):112–9.

- 21. WHO. HIV drug resistance report 2021. World Health Organization 2021; 2021.
- 22. World Health Organization. HIV drug resistance report 2019. GENEVA: WHO; 2019.
- 23. Dadi TL, Wiemers AMC, Tegene Y, Medhin G, Spigt M. Experiences of people living with HIV in low- and middle-income countries and their perspectives in self-management: a meta-synthesis. AIDS Res Ther. 2024;21(1):7.
- Dadi TL, Tegene Y, Vollebregt Ň, Medhin G, Spigt M. The importance of self-management for better treatment outcomes for HIV patients in a lowincome setting: perspectives of HIV experts and service providers. AIDS Res Therapy. 2024;21(28).
- Lorig KR, Holman H. Self-management education: history, de nition, outcomes, and mechanisms. Ann Behav Med. 2003;26(1):1–7.
- Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication selfmanagement program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003;50(2):187–99.
- 27. Webel AR. Testing a peer-based symptom management intervention for women living with HIV/AIDS. AIDS Care. 2010;22(9):1029–40.
- Areri HA, Marshall A, Harvey G. Interventions to improve self-management of adults living with HIV on antiretroviral therapy: a systematic review. PLoS ONE. 2020;15(5):e0232709.
- 29. Makoae LN, Gree M, René D, Phetlhu, Leana R, Uys, Joanne R, Naidoo TW, Kohi et al. Coping with HIV/AIDS Stigma in ve African countries. J Assoc Nurses AIDS Care. 2008;19.
- Swendeman D, Ingram BL, Rotheram-Borus MJ. Common elements in selfmanagement of HIV and other chronic illnesses: an integrative framework. AIDS Care. 2009;21(10):1321–34.
- Aantjes CJ, Ramerman L, Bunders JF. A systematic review of the literature on self-management interventions and discussion of their potential relevance for people living with HIV in sub-saharan Africa. Patient Educ Couns. 2014;95(2):185–200.
- Crowley T, Rohwer A. Self-management interventions for adolescents living with HIV: a systematic review. BMC Infect Dis. 2021;21(1):431.
- Buh A, Deonandan R, Gomes J, Krentel A, Oladimeji O, Yaya S. Barriers and facilitators for interventions to improve ART adherence in sub-saharan African countries: a systematic review and meta-analysis. PLoS ONE. 2023;18(11):e0295046.
- Ryan P, Sawin KJ. The individual and family self-management theory: background and perspectives on context, process, and outcomes. Nurs Outlook. 2009;57(4):217–25. e6.
- Shepherd J, Gurney S, Patel HP. Shared decision making and personalised care support planning: pillars of integrated care for older people. Clin Integr Care. 2022;12.
- Lawless MT, Tieu M, Chan RJ, Hendriks JM, Kitson A. Instruments measuring self-care and self-management of chronic conditions by community-dwelling older adults: a scoping review. J Appl Gerontol. 2023;42(7):1687–709.
- Brady TJ, Sacks JJ, Terrillion AJ, Colligan EM. Operationalizing surveillance of chronic disease self-management and self-management support. Prev Chronic Dis. 2018;15:E39.
- Crowley T, Van der Merwe A, Kidd M, Skinner D. Measuring adolescent HIV self-management: an instrument development study. AIDS Behav. 2020;24(2):592–606.
- Webel AR, Asher A, Cuca Y, Okonsky JG, Kaihura A, Dawson Rose C, et al. Measuring HIV self-management in women living with HIV/AIDS: a psychometric evaluation study of the HIV self-management scale. J Acquir Immune De c Syndr. 2012;60(3):e72–81.
- Wallston KA, Osborn CY, Wagner LJ, Hilker KA. The perceived medical condition self-management scale applied to persons with HIV/AIDS. J Health Psychol. 2011;16(1):109–15.
- Mallory O, Johnson TBN, Dilworth S, Morin SF, Remien RH, Chesney MA. The role of self-e cacy in HIV treatment adherence: validation of the HIV treatment adherence self-e cacy scale (HIV-ASES). J Behav Med. 2007;30(5):359–70.
- 42. Wiemers AMC, Dadi TL, Tegene Y, Spigt M. Self-management experiences of people living with HIV in low- and middle income countries qualitative review. Maastricht University and Hawassa University; 2021.
- 43. Vitoratou S, Pickles A. A note on contemporary psychometrics. J Ment Health. 2017;26(6):486–8.
- Cano SJ, Hobart JC. The problem with health measurement. Patient Prefer Adherence. 2011;5:279–90.
- 45. Tegene Legese Dadi HK, Medhin G, Spigt M. Development and validation of a self-management questionnaire for people living with HIV in low- and middle-income countries. HIV-SM LMIC tool; 2024.

- Central Statistical Agency (CSA). [Ethiopia]. Population projections for Ethiopia 2007–2037. Addis Ababa: Population Census Commission; 2013.
- 47. Federal Democratic Republic of Ethiopia MInistry of Health. Health Sector Transformation Plan-II. Addis Ababa2021.
- Federal Democratic Republic of Ethiopia Ministry of Health. Health Sector Medium-Term Development and Investment Plan (HSDIP). Addis Ababa2016.
- Gunawan J, Marzilli C, Aungsuroch Y. Establishing appropriate sample size for developing and validating a questionnaire in nursing research. Belitung Nurs J. 2021;7(5):356–60.
- Emmanuelle Anthoine LM, Regnault A, V ronique S bille and Jean-Benoit Hardouin. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12(176).
- Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.
- Frost MH, Reeve BB, Liepa AM, Stau er JW, Hays RD, Mayo FDAP-ROCMG. What is su cient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007;10(Suppl 2):S94–105.
- Grand-Guillaume-Perrenoud JA, Geese F, Uhlmann K, Blasimann A, Wagner FL, Neubauer FB, et al. Mixed methods instrument validation: evaluation procedures for practitioners developed from the validation of the Swiss instrument for evaluating interprofessional collaboration. BMC Health Serv Res. 2023;23(1):83.
- Oberg U, Hornsten A, Isaksson U. The self-management assessment scale: development and psychometric testing of a screening instrument for person-centred guidance and self-management support. Nurs Open. 2019;6(2):504–13.
- Mezo PG. The self-control and self-management scale (SCMS): development of an adaptive self-regulatory coping skills instrument. J Psychopathol Behav Assess. 2008;31(2):83–93.

- THE SELF-CONTROL AND SELF-MANAGEMENT SCALE (SCMS). A general measure of self-control and self-management skills. 2005.
- Kim GS, Chu SH, Park Y, Choi JY, Lee JI, Park CG, McCreary LL. Psychometric properties of the Korean version of the HIV self-management scale in patients with HIV. J Korean Acad Nurs. 2015;45(3).
- Kadriye Ercikan H-H, Por, Guo H. Cross-cultural validity and comparability in assessments of complex constructs. In: Piacentini NFM, editor. Innovating assessments to measure and support complex skills. OECD iLibrary; 2023.
- Bagheri Z, Chamanpara P, Jafari P, Balhara YPS, Arya S, Ransing R et al. Cross-cultural measurement invariance of the quality of life enjoyment and satisfaction questionnaire-short form across ten countries: the application of Bayesian approximate measurement invariance. BMC Psychol. 2022;10(1).
- Linn Gjersing JRC. Thomas Clausen. Cross-cultural adaptation of research instruments: language, setting, time and statistical considerations. BMC Medical Research Methodology; 2010.
- 61. Marcoulides TRaGA. Introduction to Psychometric Theory. Taylor and Francis Group, LLC; 2011.
- Boateng GO, Neilands TB, Frongillo EA, Melgar-Quinonez HR, Young SL. Best practices for developing and validating scales for health, social, and behavioral research: a primer. Front Public Health. 2018;6:149.
- Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-o value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26(3):297–307.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional a liations.